Compare Organon & Co. Common Stock (OGN) vs PBF Energy Inc. Class A Common Stock (PBF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs PBF Energy Inc. Class A Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while PBF Energy Inc. Class A Common Stock trades at $89.57 (market cap $10.81B). The key difference: PBF Energy Inc. Class A Common Stock is far larger — about 3× Organon & Co. Common Stock's market cap, and PBF Energy Inc. Class A Common Stock pays the higher dividend (1.21%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PBF Energy Inc. Class A Common Stock for 1 Days on average.
| OGN | PBF | |
|---|---|---|
Market Cap | $3.62B | $10.81B |
Volume | 2,892,999 | 3,399,980 |
Sector | Health | Energy |
52-Week High | $13.81 | $91.17 |
52-Week Low | $5.70 | $26.02 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $11.04B | $12.43B |
Dividend Yield | 0.58% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PBF Energy trades at $91.17, up 7.23% in the last 24 hours and near its 52-week high, reflecting strong bullish momentum. The stock shows robust technical strength with a bullish moving average signal and trades above key support levels. Fundamentally, the company is transitioning from a net loss of $158.5 million in 2025 to a projected net profit of $1.4 billion in 2026, driven by restored refinery operations and significant debt reduction. Recent earnings beats, including a Q2 2026 EPS of $6.22 versus $4.15 expected, highlight operational improvements.
The outlook for PBF is positive with strong earnings growth and discounted valuation metrics, but risks include volatile refining margins and geopolitical influences on oil prices. Analyst sentiment is mixed with a consensus price target of $88.75, below the current price, suggesting caution despite the bullish technical setup. Investors should weigh the strong profitability rebound against potential headwinds from energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About PBF Energy Inc. Class A Common Stock
PBF Energy refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics assets supporting its refining business.
Read more on PBF →
